Renal and urinary disorders – page 21

Fosfomycin trometamol versus drug combination for treating acute E. coli pyelonephritis in women aged 75 years and older

Fosfomycin trometamol versus drug combination for treating acute E. coli pyelonephritis in women aged 75 years and older

Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Fosfomycin versus drug combination for oral step‑down treatment of febrile urinary tract infections caused by E. coli in men

Fosfomycin versus drug combination for oral step‑down treatment of febrile urinary tract infections caused by E. coli in men

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

Preventing urinary tract infections in infants and children under 2 years with oral Escherichia coli strain Nissle 1917 probiotic: a randomized controlled trial

Preventing urinary tract infections in infants and children under 2 years with oral Escherichia coli strain Nissle 1917 probiotic: a randomized controlled trial

Phase Ib/II Study of LP-184 in Patients with Advanced or Metastatic Urothelial Carcinoma

Phase Ib/II Study of LP-184 in Patients with Advanced or Metastatic Urothelial Carcinoma

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Evaluation of zirconium-89 crefmirlimab berdoxam PET imaging for monitoring renal allograft rejection in kidney transplant recipients

Evaluation of zirconium-89 crefmirlimab berdoxam PET imaging for monitoring renal allograft rejection in kidney transplant recipients